Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-05-28
2009-08-11
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S423000
Reexamination Certificate
active
07572770
ABSTRACT:
Substances that inhibit the action of the members of the IL-1β/NF-κB pathway can be used for protecting and preserving β-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and/or pyrrolidinedithiocarbamate (PDTC) for the treatment or prophylaxis of type 2 diabetes, as well as a method for the treatment of type 2 diabetes.
REFERENCES:
patent: 6159460 (2000-12-01), Thompson et al.
patent: 6294170 (2001-09-01), Boone et al.
patent: 2001/0053764 (2001-12-01), Sims et al.
patent: 1 018 514 (2000-07-01), None
patent: 1018514 (2000-07-01), None
Giannoukakis et a., Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro, 1999, Diabetes, vol. 48, pp. 1730-1736.
Welsh et al., Is there a role for locally produced interlukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets?, 2005, Diabetes, vol. 54, pp. 3238-3244.
Donath et al., Mechanisms of beta-cell death in Type 2 diabetes, 2005, Diabetes, vol. 54, Supplement 2, pp. S108-S113.
Dinarello et al., “Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro”, Immunology Today, vol. 12, No. 11, 1991, pp. 404-410.
Mandrup-Poulsen et al., “Involvement of interleuken 1 and interleuken 1 antagonist in pancreatic and beta-cell destruction in insulin-dependent diabetes mellitus”, Cytokine, vol. 5, No. 3, 1993, pp. 185-191.
Meier et al., “IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?”, Journal of Clinical Endocrinology & Metabolism, vol. 87, No. 3, 2002, pp. 1184-1188.
Donath et al., “Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammornys obesus during development of diabetes”, Diabetes, vol. 48, No. 4, 1999, pp. 738-744.
Bedoya et al., “Pyrrolidine dithiocarbamate prevents IL-1-induced nitric oxide synthase MRNA, but not superoxide dismutase MRNA, in insulin producing cells”, Biochemical and Biophysical Research Communications, Academic Press Inc., Florida, vol. 210, No. 3, 1995, pp. 816-822.
Yamamoto et al., “Role of the NF-kappaB pathway in the pathogenesis of human disease states”, Current Molecular Medicine, Bentham Science Publishers, Great Britain, vol. 1, No. 3, 2001, pp. 287-296.
Flodstroem et al., “Cytokines activate the nuclear factor KAPPAB (NF-KAPPAB) and inducenitric oxide production in human pancreatic islets”, FEBS Letters, Elsevier Science Publishers, The Netherlands, vol. 385, No. 1/2, 1996, pp. 4-6.
Maedler et al., “Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets”, Journal of Clinical Investigation, vol. 110, No. 6, 2002, pp. 851-860.
Blocking IL-1: Interleukin 1 receptor antagonist in vivo and in vitro, Charles A. Dinarello, et al.,Immunology Today, vol. 12 No. 11 199, pp. 404-410.
Involvement of Interleukin 1 and Interleukin 1 Antagonist in Pancreatic B-Cell Destruction in Insulin-Dependent Diabetes Mellitus, Thomas Mandrup-Poulson, et al.,Cytokine, vol. 5, No. 3 (May), 1993 pp. 185-191.
Il-1 Receptor Antagonist Serum Levels Are Increased in Human Obesity: A Possible Link to the Resistance to Leptin?, Christoph A. Meier,et al.,The Journal of Clinical Endocrinology&Metabolism87(3):1184-1188.
Hyperglucemia-Induced B-Cell Apoptosis in Pancreatic Islets of Psammomys obesus During Development of Diabetes, Marc Y. Donath, et al.,Diabetes, vol. 48 Apr. 1999, 738-744.
Pyrrolidine Dithiocarbamate Prevents IL-1-Induced Nitric Oxide Synthase mRNA, but not Superoxide Dismutase mRNA, in Insulin Producing Cells, F.J. Bedoyua, et al.,Biochemical and Biophysical Research Communications, vol. 210, No. 3 1995, pp. 816-822.
Role of the NF-kB Pathway in the Pathogenesis of Human Disease States, Yumi Yamamoto and Richard Gaynor,Current Molecular Medicine2001, 1, pp. 287-296.
Cyokines Activate the Nuclear Factor kB (NF-kB) and Induce Nitric Oxide Production in Human Pancreatic Islets, Maline Flodström , et al.,Federation of European Biochemical Societies285 (1996) 4-6.
Glucose-induced B cell Production of IL-1B contributes to Glucotoxicity in Human Pancreatic Islets, Kathrin Maedler, et al.,The Journal of Clinical Investigation, Sep. 2002, vol. 110, No. 6, pp. 851-860.
Hyperglycaemia as an Inducer as well as a Consequence of Impaired Islet Cell Function and Insulin Resistance: Implications for the Management of Diabetes, R.H. Under, et al.,Diabetologia, (1985) 28: 119-121.
Monolayer Culture of Adult Rat Pancreatic Islets on Extracellular Matrix: Modulation of B-Cell Function by Chronic Exposure to High Glucose, Nurit Kaiser, et al.,Endocrinology, vol. 129, No. 4, pp. 2067-2075.
Chronic Hypergycemia Is Associated with Impaired Glucose Influence on Insulin Secretion, A Study in Normal Rats Using Chronic In Vivo Glucose Infusions, L. J. Leahy, et al.,J. Clinical Invest., vol. 77 Mar. 1986, pp. 908-915.
Perspective in Diabetes, Type II Diabetes, Glucose “Non-Sense,” and Islet Desensitization, R. Paul Robertson,Diabetes, vol. 38, Dec. 1989, pp. 1501-1505.
Glucose Toxicity, Luciano Rossetti, M.D., et al.,Diabetes Care, vol. 13, No. 6, Jun. 1990, pp. 610-630.
Prolonged Exposure of Human Pacreatic Islets to High Glucose Concentrations in Vitro Impairs the B-Cell Function, Decio L. Elizirik, et al.J. Clin. Invest., vol. 90, Oct. 1992, pp. 1263-1268.
Impaired B-Cell Functions Induced by Chronic Exposure of Cultured Human Pancreatic Islets to High Glucose, Sonya Marchak, et al.,Diabetes, vol. 48m Jun. 1999, pp. 1230-1236.
Glucose Induces B-Cell Apoptosis Via Upregulation of The Fas Receptor in Human Islets, Kathrin Maedler, et al.,Diabetes, vol. 50, Aug. 2001, pp. 1683-1690.
High Glucose Causes Apoptosis in Cultured Human Pancreatic Islets of Langerhans, A Potential Role for Regulation of Specific Bcl Family Genes Toward an Apoptotic Cell Death Program, Massimo Federici, et al.,Diabetes, vol. 50, Jun. 2001, pp. 1290-1301.
Glucose and Tolbutamide Induce Apoptosis in Pancreatic B-Cells, Ioulia B. Efanova, et al.,The Journal of Biological Chemistry, vol. 273, No. 50, Issue of Dec. 11, pp. 33501-33507.
Distinct Effects of Saturated and Monounsaturated Fatty Acids on B-Cell Turnover and Function, K. Maedler, et al.,Diabetes, vol. 50, Jan. 2001, pp. 69-76.
Long Term Effects of Aminoguanidine on Insulin Release and Biosynthesis: Evidence That the Formation of Advanced Glycosylation End Products Inhibits B Cell Function, Yuji Tajiri, et al.,Endocrinology, vol. 138, No. 1, pp. 273-280.
Preservation of Insulin mRNA Levels and Insulin Secreation in HIT Cells by Avoidance of Chronic Exposure to High Glucose Concentrations, R. Paul Robertson,J. Clin. Invest., vol. 90, Aug. 1992, pp. 320-325.
Differentiating Glucose Toxicity From Glucose Desensitization: A New Message From the Insulin Gene, R. Paul Robertson, et al.,Diabetes Center and the Division of Diabetes, University of Minnesota Medical School,1994.
The Role of Interleukin-1 in the Pathogenesis of IDDM, T. Mandrup-Poulsen,Diabetologia(1996) 39: pp. 1005-1029.
Cytokines Cause Functional and Structural Damage to Isolated Islets of Langerhans, T. Mandrup-Poulsen, et al.,Allergy1985, 40, pp. 424-429.
Cytoxicity of Human pI 7 Interleukin-1 for Pancreatic Islets of Langerhans, Klaus Bendtzen, et al.,Science, vol. 232, pp. 1545-1547.
Interleukin 1 Dose-Dependently Affects the Biosynthesis of (pro) Insulin in Isolated Rat Islets of Langerhans, G.A Spinas, et al.,Diabetologia, (1987) 30: pp. 474-480.
Affinity-Purified Human Interleukin 1 is Cytotoxic to Isolated Islets of Langerhans, T. Mandrup-Poulsen,Diabetaologia,(1987) 29: pp. 63-67.
Low Concentrations of Interleukin—1 Stimulate and High Concentrations Inhibit Insulin Release from Isolated Rat Islets of Langerhans, Giatgen A. Spinas, et al.,ACTA Endocrin
Birch & Stewart Kolasch & Birch, LLP
Dang Ian
Landsman Robert
University of Zurich
LandOfFree
Use of an interleukin 1 receptor antagonist and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of an interleukin 1 receptor antagonist and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of an interleukin 1 receptor antagonist and/or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4099195